David Hinchman, MD
Cardiovascular Disease · Boise, IDNPI 1710914528
Payments from drug & device makers
Across 706 payments — averaging $2307.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$358K
- Eli Lilly$260K
- Novartis$231K
- E.r. Squibb & Sons, L.L.C.$203K
- CSL Behring$194K
- Boehringer Ingelheim$74K
- plus $309K from 34 others
Across 4 payments — averaging $21,873 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$87K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,628,950 in reported general payments places this provider in the 95th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Boise
- Robyn BrydeBoise$27K
- Matthew NelsonBoise$6K
- Beth MalaskyBoise$5K
- Stefanie FryBoise$4K
- Samual BassBoise$4K
- Timothy MooreBoise$3K
- Michael RichBoise$2K
- Troy BadgerBoise$2K
- Jon BergsetBoise$636
- Steven FonkenBoise$598
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.